Drug intelligence / Profile preview

MIL77

Development stage: Phase 1
Lead developer: Mabworks Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MIL77 is an investigational, afucosylated human-mouse chimeric monoclonal-antibody cocktail for **Ebola virus disease**. It comprises three anti-Zaire ebolavirus glycoprotein antibodies—MIL77-1, MIL77-2, and MIL77-3—derived from the variable regions of ZMapp antibodies 2G4, 4G7, and 13C6, respectively. The antibodies bind distinct regions of Ebola virus glycoprotein, including the GP base and glycan-cap or secreted-glycoprotein regions, to neutralize viral entry; afucosylation is intended to enhance Fcγ receptor-mediated antibody-dependent cellular cytotoxicity. MIL77 was developed using engineered CHO production cells and completed a Chinese Phase 1 healthy-volunteer study. ([journals.asm.org](https://journals.asm.org/doi/10.1128/jvi.00685-24))

Other names: Recombinant anti-Ebola virus monoclonal antibody combination injection

Targets

sGP (Ebola virus secreted glycoprotein)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on MIL77.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIL77.